Balchem Corp
At today's price, Balchem Corp (BCPC) is priced for +20.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Balchem is a specialty-ingredients compounder that has now posted 27 consecutive quarters of year-over-year adjusted-EBITDA growth, with all three segments growing in the first quarter and Human Nutrition and Health, the largest, up 8.3% to $171.6 million [Source: Balchem Q1 2026 earnings release, April 30 2026]. • The price is the risk: today's level requires operating profit to compound at roughly 22% a year for five years, well above what the company has actually delivered, so the bet is on
Is BCPC overvalued? See what's priced in →
409 institutional managers reported holding BCPC in 13F filings for the quarter ended 2026-03-31. Together they hold about 87% of the company; the top 10 hold 51%. 49 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 419k shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (1.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BCPC has cut its share count 0.9% over the past five years, spending $193.30M on repurchases. It pays a dividend, and has for 12 years running, raised 11 years straight; the current rate is $0.96 a share annually. Cash returned over the past three years: $84.64M in dividends and $129.55M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BCPC over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BCPC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | +1.8% | -5.2% |
| 2023-10-28 | -5.4% | +29.3% |
| 2024-02-17 | +1.9% | -3.8% |
| 2024-05-04 | +2.8% | +6.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BCPC's latest 8-K filings: 2026-06-22 (items 5.07); 2026-04-30 (items 2.02, 9.01); 2026-02-20 (items 2.02, 9.01); 2026-02-19 (items 5.02, 9.01); 2025-12-10 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.